Thiazolidinediones and antiblastics in primary human anaplastic thyroid cancer cells

Clinical Endocrinology

Volumn 70, Issue 6, 2009, Pages 946-953

  Antonelli, Alessandro ^a   Ferrari, Silvia Martina ^a   Fallahi, Poupak ^a   Berti, Piero ^a   Materazzi, Gabriele ^a   Minuto, Michele ^a   Giannini, Riccardo ^a   Marchetti, Ivo ^b   Barani, Lucio ^a   Basolo, Fulvio ^a   Ferrannini, Ele ^a   Miccoli, Paolo ^a  

^a UNIVERSITY OF PISA   (Italy)

^b UNIVERSITY HOSPITAL OF PISA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; BLEOMYCIN; CISPLATIN; GEMCITABINE; PIOGLITAZONE; ROSIGLITAZONE;

ANAPLASTIC CARCINOMA; ARTICLE; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG ACTIVITY; GENE MUTATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; PRIORITY JOURNAL; THYROID CANCER; THYROID FOLLICLE CELL;

CARCINOMA; CELL PROLIFERATION; GROWTH INHIBITORS; HUMANS; THIAZOLIDINEDIONES; THYROID NEOPLASMS; TUMOR CELLS, CULTURED;

EID: 66149137603     PISSN: 03000664     EISSN: 13652265     Source Type: Journal    
DOI: 10.1111/j.1365-2265.2008.03415.x     Document Type: Article

References (45)

1. Ain, K.B. (1998) Anaplastic thyroid carcinoma: behavior, biology, and therapeutic approaches. Thyroid, 8, 715 726. (Pubitemid 28405160)
2. Giuffrida, D. Gharib, H. (2000) Anaplastic thyroid carcinoma: current diagnosis and treatment. Annals of Oncology, 11, 1083 1089.
3. Junor, E.J., Paul, J. Reed, N.S. (1992) Anaplastic thyroid carcinoma: 91 patients treated by surgery and radiotherapy. European Journal of Surgical Oncology, 18, 83 88.
4. Brignardello, E., Gallo, M., Baldi, I. et al. (2007) Anaplastic thyroid carcinoma: clinical outcome of 30 consecutive patients referred to a single institution in the past 5 years. European Journal of Endocrinology, 156, 425 430. (Pubitemid 46672642)
5. Pudney, D., Lau, H., Ruether, J.D. et al. (2007) Clinical experience of the multimodality management of anaplastic thyroid cancer and literature review. Thyroid, 17, 1243 1250.
6. Newell, D.R. (2001) Flasks, fibres and flanks - pre-clinical tumour models for predicting clinical antitumour activity. British Journal of Cancer, 84, 1289 1290. (Pubitemid 32522092)
7. Schroyens, W., Tueni, E., Dodion, P. et al. (1990) Validation of clinical predictive value of in vitro colorimetric chemosensitivity assay in head and neck cancer. European Journal of Cancer, 26, 834 838. (Pubitemid 20328561)
8. Voigt, W., Bulankin, A., Muller, T. et al. (2000) Schedule-dependent antagonism of gemcitabine and cisplatin in human anaplastic thyroid cancer cell lines. Clinical Cancer Research, 6, 2087 2093. (Pubitemid 30305109)
9. Ain, K.B., Egorin, M.J. DeSimone, P.A. (2000) Treatment of anaplastic thyroid carcinoma with paclitaxel: phase 2 trial using ninety-six-hour infusion. Collaborative Anaplastic Thyroid Cancer Health Intervention Trials (CATCHIT) Group. Thyroid, 10, 587 594.
10. Copland, J.A., Marlow, L.A., Kurakata, S. et al. (2006) Novel high-affinity PPARγ agonist alone and in combination with paclitaxel inhibits human anaplastic thyroid carcinoma tumor growth via p21WAF1/CIP1. Oncogene, 25, 2304 2317.
11. Grommes, C., Landreth, G.E. Heneka, M.T. (2004) Antineoplastic effects of peroxisome proliferator-activated receptor γ agonists. Lancet Oncology, 5, 419 429. (Pubitemid 38878045)
12. Antonelli, A., Rotondi, M., Ferrari, S.M. et al. (2006) Interferon-γ-inducible α-chemokine CXCL10 involvement in Graves' ophthalmopathy: modulation by peroxisome proliferator-activated receptor-γ agonists. Journal of Clinical Endocrinology and Metabolism, 91, 614 620. (Pubitemid 43236933)
13. Weng, J.R., Chen, C.Y., Pinzone, J.J. et al. (2006) Beyond peroxisome proliferator-activated receptor γ signaling: the multi-facets of the antitumor effect of thiazolidinediones. Endocrine Related Cancer, 13, 401 413. (Pubitemid 43886665)
14. Panigrahy, D., Huang, S., Kieran, M.W. et al. (2005) PPARγ as a therapeutic target for tumor angiogenesis and metastasis. Cancer Biology and Therapy, 4, 687 693. (Pubitemid 41351164)
15. Ohta, K., Endo, T., Haraguchi, K. et al. (2001) Ligands for peroxisome proliferator-activated receptor γ inhibit growth and induce apoptosis of human papillary thyroid carcinoma cells. Journal of Clinical Endocrinology and Metabolism, 86, 2170 2177. (Pubitemid 32472935)
16. Klopper, J.P., Hays, W.R., Sharma, V. et al. (2004) Retinoid X receptor-γ and peroxisome proliferator-activated receptor-γ expression predicts thyroid carcinoma cell response to retinoid and thiazolidinedione treatment. Molecular Cancer Therapeutics, 3, 1011 1020.
17. Philips, J.C., Petite, C., Willi, J.P. et al. (2004) Effect of peroxisome proliferator-activated receptor γ agonist, rosiglitazone, on dedifferentiated thyroid cancers. Nuclear Medicine Communications, 25, 1183 1186. (Pubitemid 39614279)
18. Park, J.W., Zarnegar, R., Kanauchi, H. et al. (2005) Troglitazone, the peroxisome proliferator-activated receptor-γ agonist, induces antiproliferation and redifferentiation in human thyroid cancer cell lines. Thyroid, 15, 222 231. (Pubitemid 40418689)
19. Frohlich, E., Machicao, F. Wahl, R. (2005) Action of thiazolidinediones on differentiation, proliferation and apoptosis of normal and transformed thyrocytes in culture. Endocrine-Related Cancer, 12, 291 303. (Pubitemid 40896448)
20. Aiello, A., Pandini, G., Frasca, F. et al. (2006) Peroxisomal proliferator-activated receptor-γ agonists induce partial reversion of epithelial-mesenchymal transition in anaplastic thyroid cancer cells. Endocrinology, 147, 4463 4475. (Pubitemid 44268398)
21. Kebebew, E., Peng, M., Reiff, E. et al. (2006) A phase II trial of rosiglitazone in patients with thyroglobulin-positive and radioiodine-negative differentiated thyroid cancer. Surgery, 140, 960 966.
22. Tepmongkol, S., Keelawat, S., Honsawek, S. et al. (2008) Rosiglitazone effect on radioiodine uptake in thyroid carcinoma patients with high thyroglobulin but negative total body scan: a correlation with the expression of peroxisome proliferator-activated receptor-γ. Thyroid, 18, 697 704.
23. Sahin, M., Allard, B.L., Yates, M. et al. (2005) PPARγ staining as a surrogate for PAX8/PPARγ fusion oncogene expression in follicular neoplasms: clinicopathological correlation and histopathological diagnostic value. Journal of Clinical Endocrinology and Metabolism, 90, 463 468. (Pubitemid 40116695)
24. Hayashi, N., Nakamori, S., Hiraoka, N. et al. (2004) Antitumor effects of peroxisome proliferator activate receptor γ ligands on anaplastic thyroid carcinoma. International Journal of Oncology, 24, 89 95.
25. Sherman, S.I. (2003) Thyroid carcinoma. Lancet, 361, 501 511. (Pubitemid 36173719)
26. Giannini, R., Ugolini, C., Lupi, C. et al. (2007) The heterogeneous distribution of BRAF mutation supports the independent clonal origin of distinct tumor foci in multifocal papillary thyroid carcinoma. Journal of Clinical Endocrinology and Metabolism, 92, 3511 3516. (Pubitemid 47435328)
27. Salvatore, G., Giannini, R., Faviana, P. et al. (2004) Analysis of BRAF point mutation and RET/PTC rearrangement refines the fine-needle aspiration diagnosis of papillary thyroid carcinoma. Journal of Clinical Endocrinology and Metabolism, 89, 5175 5180. (Pubitemid 39391466)
28. Fiore, L., Pollina, L.E., Fontanini, G. et al. (1997) Cytokine production by a new undifferentiated human thyroid carcinoma cell line, FB-1. Journal of Clinical Endocrinology and Metabolism, 82, 4094 4100. (Pubitemid 27525520)
29. Berridge, M.V., Herst, P.M. Tan, A.S. (2005) Tetrazolium dyes as tools in cell biology: new insights into their cellular reduction. Biotechnology Annual Review, 11, 127 152. (Pubitemid 41510276)
30. Gutiérrez-Cañas, I., Rodrìguez-Henche, N., Bolaños, O. et al. (2003) VIP and PACAP are autocrine factors that protect the androgen-independent prostate cancer cell line PC-3 from apoptosis induced by serum withdrawal. British Journal of Pharmacology, 139, 1050 1058. (Pubitemid 36877404)
31. Gillman, G. (2005) The Pharmacological Basis of Therapeutics. McGraw-Hill, New York.
32. Fridborg, H., Nygren, P. Larsson, R. (1995) Relationship between pharmacokinetic parameters in patients and cytotoxicity in vitro of standard and investigational anticancer drugs. Anticancer Drugs, 6, 64 69.
33. Abbruzzese, J.L., Grunewald, R., Weeks, E.A. et al. (1991) A phase I clinical, plasma, and cellular pharmacology study of gemcitabine. Journal of Clinical Oncology, 9, 491 498.
34. Martelli, M.L., Iuliano, R., Le Pera, I. et al. (2002) Inhibitory effects of peroxisome poliferator-activated receptor γ on thyroid carcinoma cell growth. Journal of Clinical Endocrinology and Metabolism, 87, 4728 4735. (Pubitemid 35247068)
35. Moretti, F., Farsetti, A., Soddu, S. et al. (1997) p53 re-expression inhibits proliferation and restores differentiation of human thyroid anaplastic carcinoma cells. Oncogene, 14, 729 740. (Pubitemid 27095865)
36. Crescioli, C., Cosmi, L., Borgogni, E. et al. (2007) Methimazole inhibits CXC chemokine ligand 10 secretion in human thyrocytes. Journal of Endocrinology, 195, 145 155. (Pubitemid 350056008)
37. Isley, W.L. (2003) Hepatotoxicity of thiazolidinediones. Expert Opinion on Drug Safety, 2, 581 586.
38. Dollner, R., Granzow, C., Werner, J.A. et al. (2004) Is there a role for chemosensitivity tests in head and neck cancer? Onkologie, 27, 310 315. (Pubitemid 39279343)
39. Otto, C., Lehrke, M. Goke, B. (2002) Novel insulin sensitizers: pharmacogenomic aspects. Pharmacogenomics, 3, 99 116. (Pubitemid 34285243)
40. Huang, J.W., Shiau, C.W., Yang, Y.T. et al. (2005) Peroxisome proliferator-activated receptor γ-independent ablation of cyclin D1 by thiazolidinediones and their derivatives in breast cancer cells. Molecular Pharmacology, 67, 1342 1348.
41. Busnardo, B., Daniele, O., Pelizzo, M.R. et al. (2000) A multimodality therapeutic approach in anaplastic thyroid carcinoma: study on 39 patients. Journal of Endocrinological Investigation, 23, 755 761. (Pubitemid 32041056)
42. Davies, G.F., Roesler, W.J., Juurlink, B.H. et al. (2005) Troglitazone overcomes doxorubicin-resistance in resistant K562 leukemia cells. Leukemia and Lymphoma, 46, 1199 1206. (Pubitemid 41087027)
43. Kanbe, E., Abe, A., Towatari, M. et al. (2003) DR1-like element in human topoisomerase IIα gene involved in enhancement of etoposide-induced apoptosis by PPARγ ligand. Experimental Hematology, 31, 300 308. (Pubitemid 36407606)
44. Salvatore, G., De Falco, V., Salerno, P. et al. (2006) BRAF is a therapeutic target in aggressive thyroid carcinoma. Clinical Cancer Research, 12, 1623 1629.
45. Begum, S., Rosenbaum, E., Henrique, R. et al. (2004) BRAF mutations in anaplastic thyroid carcinoma: implications for tumor origin, diagnosis and treatment. Modern Pathology, 17, 1359 1363. (Pubitemid 39472990)